

## DAFTAR PUSTAKA

1. Meghji J, Mortimer K, Agusti A, Allwood BW, Asher I, Bateman ED, et al. Improving lung health in low-income and middle-income countries: from challenges to solutions. *Lancet* (London, England). 2021; 397: 928–40.
2. The Global Initiative for Chronic Obstructive Lung Disease. GLOBAL STRATEGY FOR PREVENTION, DIAGNOSIS AND MANAGEMENT OF COPD: 2023 Report. 2023: 4–5.
3. Bollmeier SG, Hartmann AP. Management of chronic obstructive pulmonary disease: A review focusing on exacerbations. *Am J Heal Pharm AJHP Off J Am Soc Heal Pharm.* 2020; 77: 259–68..
4. Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. *Eur Respir J.* 2019; 53: 56-70.
5. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet Respir Med.* 2017; 5: 691–706.
6. Safiri S, Carson-Chahhoud K, Noori M, Nejadghaderi SA, Sullman MJM, Ahmadian Heris J, et al. Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990-2019: Results from the Global Burden of Disease Study 2019. *BMJ.* 2022; 2: 130-54.
7. Kemenkes RI. Hasil Riset Kesehatan Dasar (Riskesdas) 2018. Jakarta: Badan Penelitian dan Pengembangan Kesehatan Kementerian RI.
8. Memon MA, Faryal S, Brohi N, Kumar B. Role of the DECAF Score in Predicting In-hospital Mortality in Acute Exacerbation of Chronic Obstructive Pulmonary Disease. *Cureus.* 2019; 11: 48-56.
9. Pavord ID, Jones PW, Burgel P-R, Rabe KF. Exacerbations of COPD. *Int J Chron Obstruct Pulmon Dis.* 2016; 11: 21-30.
10. Echevarria C, Gray J, Hartley T, Steer J, Miller J, Simpson AJ, et al. Home treatment of COPD exacerbation selected by DECAF score: a non-inferiority, RCT and economic evaluation. *Thorax.* 2018; 73:713–22.

11. Frida W, Makabhah DN, Aphridasari J, Raharjo F, Departemen S, Dan P, et al. Perbandingan Skor BAP 65 dan Skor DECAF Sebagai Prediktor Luaran PPOK Eksaserbasi di IGD RSUD Dr. Moewardi. *J Respir Indo*. 2017; 37: 31-40.
12. Nadeem I, Light A, Donaldson C, Khatana UF, Bagmane D, Thomas E, et al. Use of DECAF scoring system to facilitate early discharge in acute exacerbation of COPD patients: a quality improvement project at a district general hospital. *Futur Healthc J*. 2021; 8: 123-33.
13. Bellou V, Belbasis L, Konstantinidis AK, Tzoulaki I, Evangelou E. Prognostic models for outcome prediction in patients with chronic obstructive pulmonary disease: Systematic review and critical appraisal. *BMJ*. 2019; 367: 11-21.
14. Purna P, Kumar K, Bharadwaj Reddy S, Mohan B, Rajesh Reddy C. Assessment of CAUDA 70 Score in acute exacerbation of chronic obstructive pulmonary disease. *IP Indian J Immunol Respir Med*. 2020; 3: 170-80.
15. Steer J, Gibson J, Bourke SC. The DECAF score: Predicting hospital mortality in exacerbations of chronic obstructive pulmonary disease. *Thorax*. 2012; 67: 970-9.
16. Echevarria C, Steer J, Heslop-Marshall K, Stenton SC, Hickey PM, Hughes R, et al. Validation of the DECAF score to predict hospital mortality in acute exacerbations of COPD. *Thorax*. 2016; 71: 133-40.
17. Celli B, Fabbri L, Criner G, Martinez FJ, Mannino D, Vogelmeier C, et al. Definition and Nomenclature of Chronic Obstructive Pulmonary Disease: Time for Its Revision. *Am J Respir Crit Care Med*. 2022; 206: 1317-26.
18. Qureshi H, Sharafkhaneh A, Hanania NA. Chronic obstructive pulmonary disease exacerbations: latest evidence and clinical implications. *Ther Adv Chronic Dis*. 2014; 5: 212-27.
19. Antuni JD, Barnes PJ. Evaluation of Individuals at Risk for COPD: Beyond the Scope of the Global Initiative for Chronic Obstructive Lung Disease. *Chronic Obstr Pulm Dis*. 2016; 3: 653-67.
20. Pando-Sandoval A, Ruano-Ravina A, Candal-Pedreira C, Rodríguez-García C, Represas-Represas C, Golpe R, et al. Risk factors for chronic obstructive pulmonary disease in never-smokers: A systematic review. *Clin Respir J*. 2022; 16: 261-75.

21. Hagstad S, Backman H, Bjerg A, Ekerljung L, Ye X, Hedman L, et al. Prevalence and risk factors of COPD among never-smokers in two areas of Sweden - Occupational exposure to gas, dust or fumes is an important risk factor. *Respir Med.* 2015; 109: 1439–49.
22. Blanc PD, Iribarren C, Trupin L, Earnest G, Katz PP, Balmes J, et al. Occupational exposures and the risk of COPD: dusty trades revisited. *Thorax.* 2009; 64: 6–14.
23. Mahmood T, Singh RK, Kant S, Shukla A Das, Chandra A, Srivastava RK. Prevalence and etiological profile of chronic obstructive pulmonary disease in nonsmokers. *Lung India.* 2017; 34: 122–30.
24. Regalado J, Pérez-Padilla R, Sansores R, Páramo Ramirez JI, Brauer M, Paré P, et al. The effect of biomass burning on respiratory symptoms and lung function in rural Mexican women. *Am J Respir Crit Care Med.* 2006; 174: 901–5.
25. Yin P, Jiang CQ, Cheng KK, Lam TH, Lam KH, Miller MR, et al. Passive smoking exposure and risk of COPD among adults in China: the Guangzhou Biobank Cohort Study. *Lancet.* 2007; 370: 751–9.
26. Jordan RE, Cheng KK, Miller MR, Adab P. Passive smoking and chronic obstructive pulmonary disease: cross-sectional analysis of data from the Health Survey for England. *BMJ Open.* 2011; 1: 22-9.
27. Lee SJ, Kim SW, Kong KA, Ryu YJ, Lee JH, Chang JH. Risk factors for chronic obstructive pulmonary disease among never-smokers in Korea. *Int J Chron Obstruct Pulmon Dis.* 2015; 10: 497–506.
28. Dong H, Hao Y, Li D, Su Z, Li W, Shi B, et al. Risk Factors for Acute Exacerbation of Chronic Obstructive Pulmonary Disease in Industrial Regions of China: A Multicenter Cross-Sectional Study. *Int J Chron Obstruct Pulmon Dis.* 2020; 15: 2249–56.
29. Mantero M, Rogliani P, Di Pasquale M, Polverino E, Crisafulli E, Guerrero M, et al. Acute exacerbations of COPD: risk factors for failure and relapse. *Int J Chron Obstruct Pulmon Dis.* 2017; 12: 2687–97.
30. Hajian B, De Backer J, Vos W, van Geffen WH, De Winter P, Usmani O, et al. Changes in ventilation-perfusion during and after an COPD exacerbation: an

- assessment using fluid dynamic modeling. *Int J Chron Obstruct Pulmon Dis*. 2018; 13: 833–42.
31. Nagaraj C, Tabelaing C, Nagy BM, Jain PP, Marsh LM, Papp R, et al. Hypoxic vascular response and ventilation/perfusion matching in end-stage COPD may depend on hypoxia. *Eur Respir J*. 2017; 50: 1305-12.
  32. Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. *Thorax*. 2015; 60: 925–33.
  33. Mannino DM, Doherty DE, Sonia Buist A. Global Initiative on Obstructive Lung Disease (GOLD) classification of lung disease and mortality: findings from the Atherosclerosis Risk in Communities (ARIC) study. *Respir Med*. 2016; 100: 115–22.
  34. Trivedi A, Khan MA, Bade G, Talwar A. Orchestration of neutrophil extracellular traps (Nets), a unique innate immune function during chronic obstructive pulmonary disease (COPD) development. *Biomedicines*. 2021; 9: 1–25.
  35. Fortis S, Wan ES, Kunisaki K, Eyck PT, Ballas ZK, Bowler RP, et al. Increased mortality associated with frequent exacerbations in COPD patients with mild-to-moderate lung function impairment, and smokers with normal spirometry. *Respir Med X*. 2021; 3: 100-13.
  36. Krishnanand KK, D CRNBM, Praveen JVMD, D PDRM. The Use of Cauda-70 Score in Predicting the Prognosis in Patients with Acute Exacerbations of COPD. 2022; 21: 21–8.
  37. Gayaf M, Karadeniz G, Güldaval F, Polat G, Türk M. Which one is superior in predicting 30 and 90 days mortality after COPD exacerbation: DECAF, CURB-65, PSI, BAP-65, PLR, NLR. *Expert Rev Respir Med*. 2021; 15: 845–51.
  38. Archibald R, Chalmers J, Fardon T, dkk. Prediction of In-Hospital Mortality in Acute Exacerbations of COPD. *Scottish Universities Medical Journal*. 2012; 1(2): 129-39.
  39. Drechsler M, Morris J. Carbon Dioxide Narcosis. *StatPearls* 2022 [cited 2024 Jan]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK551620/>.

40. Davidson AC, Banham S, Elliott M, Kennedy D, Gelder C, Glossop A, et al. British Thoracic Society/Intensive Care Society Acute Hypercapnic Respiratory Failure Guideline Development Group. BTS guideline. *Thorax*. 2016;71(2): 1-35.
41. Chung C, Lee KN, Han K, Shin DW, Lee SW. Effect of smoking on the development of chronic obstructive pulmonary disease in young individuals: a nationwide cohort study. *Front Med*. 2023; 10: 119-28.
42. Laniado, R. Smoking and chronic obstructive pulmonary disease (COPD). *Int J Environ Res Public Health*. 2019;6(1):209-24.
43. Easter M, Bollenbecker S, Barnes JW, Krick S. Targeting Aging Pathways in Chronic Obstructive Pulmonary Disease. *Int J Mol Sci*. 2020; 21(18): 69-77.
44. Tarigan A, Abidin A. Perbandingan antara skor CAUDA-70 dengan skor BAP-65 terhadap Mortalitas pada Pasien PPOK Eksaserbasi Akut [tesis]. Medan: Universitas Sumatera Utara; 2014.
45. Cukic V. The changes of arterial blood gases in COPD during four-year period. *Med Arch*. 2014;68(1):14-8.
46. Inkrott JC. Understanding Hypoxic Drive and the Release of Hypoxic Vasoconstriction. *Air Med J*. 2016;35(4):210-6.
47. Zeng Z, Ke X, Gong S, Huang X, Liu Q, Huang X, Cheng J, Li Y, Wei L. Blood urea nitrogen to serum albumin ratio: a good predictor of in-hospital and 90-day all-cause mortality in patients with acute exacerbations of chronic obstructive pulmonary disease. *BMC Pulm Med*. 2022; 22(1):476-85.
48. Zhang J, Qin Y, Zhou C, Luo Y, Wei H, Ge H, et al.. Elevated BUN Upon Admission as a Predictor of in-Hospital Mortality Among Patients with Acute Exacerbation of COPD: A Secondary Analysis of Multicenter Cohort Study. *Int J Chron Obstruct Pulmon Dis*. 2023;18:1445-55.
49. Chen CW, Chen YY, Lu CL, Chen SC, Chen YJ, Lin MS, et al. Severe hypoalbuminemia is a strong independent risk factor for acute respiratory failure in COPD: a nationwide cohort study. *Int J Chron Obstruct Pulmon Dis*. 2015;10:1147-54.



50. Zinellu E, Fois AG, Sotgiu E, Mellino S, Mangoni AA, Carru C, et al. Serum Albumin Concentrations in Stable Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis. *J Clin Med.* 2021;10(2):269-81.
51. Durheim MT, Cyr DD, Lopes RD, Thomas LE, Tsuang WM, Gersh BJ, et al. Chronic obstructive pulmonary disease in patients with atrial fibrillation: Insights from the ARISTOTLE trial. *Int J Cardiol.* 2016;202:589–94
52. Miravittles M, Monecagudo M, Sointseva I, Alcazar B. Blood Eosinophil Counts and Their Variability and Risk of Exacerbations in COPD. *J bronconeumologi.* 2021; 57(1): 13-20.
53. Telukutla S, Vidya T, Ganesan S. BAP-65 and DECAF Scores in Predicting Outcomes in Acute Exacerbation of Chronic Obstructive Pulmonary Disease. *J Clin and Diagnostic.* 2014; 14(11): 101-4.

